CROMA
IMA is world leader in the design and manufacture of automatic machines and complete lines for the processing and packaging of pharmaceutical products.
Continuous Manufacturing is one of the main drivers of innovation in the pharmaceutical production sector. CROMA, the new continuous tablet coating equipment, is IMA’s first step in this direction.
IMA Active is working on the continuous process by rethinking currently known technologies in order to bring new proposals for customers to the market as quickly as possible. When it comes to technologies for solid oral form production, IMA Active has chosen to start with the tablet coating process because it comes between two intrinsically continuous processes already managed by IMA machines: tablet pressing and packaging. CROMA, the new continuous tablet coating equipment, is sized to work downstream of a medium-speed tablet press.
IMA is committed to supporting the change towards Continuous Manufacturing. CROMA is the first step towards continuous production. IMA’s team is ready to welcome the demand for innovation coming from companies and stakeholders, working together to design the future of pharmaceutical manufacturing.
Contact Details:
Company name: IMA S.p.A. - Active division
Website:www.ima.it
E-mail: mktg.soliddose@ima.it
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
3D Screen Printing: Enabling A New Generation of Complex Formulations
April 14th 20253D screen printing provides innovative drug development capabilities that are difficult or impossible to achieve with traditional methods, including complex multi-layered formulations, precision control over drug release profiles, and near-endless possibilities in the geometric shaping of dosage forms. In this article, learn how 3D screen printing offers unmatched flexibility to tailor formulations for specific therapeutic needs and redefines what’s possible in drug development and manufacturing.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
